16.3 C
New York

Tag: new zealand

The Wuling COVID Testing Cars will be delivered at the end of May

HONG KONG, May 23, 2022 - (ACN Newswire) - On May 13, Guo Yanhong, the supervisor of the Medical Administration and Hospital Authority of the National Health Commission,...

Top News

Currency markets remain in holding pattern

Currency markets looking for direction The currency space remained on the sidelines overnight, content to wait and watch for developments elsewhere for its next directional cues. The dollar index rose just 0.16% to 98.77. It has reversed in Asia, falling by 0.34% to 98.44 as Japanese officials talked the yen higher. 97.70 and 99.50 remain […]

Currency markets remain in holding pattern

Currency markets looking for direction The currency space remained on the sidelines overnight, content to wait and watch for developments elsewhere for its next directional cues. The dollar index rose just 0.16% to 98.77. It has reversed in Asia, falling by 0.34% to 98.44 as Japanese officials talked the yen higher. 97.70 and 99.50 remain […]

Japan jaw bones USD/JPY Lower

Both Bank of Japan Governor Kuroda, and Minister of Finance Suzuki, have been on the wires this morning with the usual watching FX closely, FX stability important rhetoric. It is the first time in many years they’ve had to resort to this playbook as USD/JPY surged above 122.00 overnight as the US/Japan rate differential widened. […]

Australian Bank Drops Anti-Crypto Stance and Embraces Stablecoins

Australia and New Zealand Banking Group Minted an Aussie dollar-denominated token.

Twitter Launches Verified NFT Profile Pictures

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

On January 20, 2022, Twitter launched a new non-fungible token (NFT) feature for its Twitter Blue users – a paid subscription service that gives its users access to premium services. This includes editing published tweets, posting longer videos, reading news without advertisements and more. Twitter Blue will allow people to showcase the NFTs they own by […]

The post Twitter Launches Verified NFT Profile Pictures appeared first on The Daily Hodl.

90’s Ape Club – An NFT collection for the 90’s kid to reshape the industry

The 90's Ape Club team is excited to introduce their collection of characters inspired from the 90's which have been designed by award winning Artist Keivo, who was named Young Cannes Lions Global 2021 Winner in Digital Art.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

The 90's was a magical time – the birth of the internet created the innovation of the website and email with the rise of CompuServe, Prodigy, AOL and more.

For the first time, people could make friends around the globe in a much more meaningful and connected way – not through pen pal letters or the digital equivalent of bulletin boards, but instead through chat rooms and GeoCities and TriPod – searches still had to be done through HotBot or AltaVista and your brand new 28.8 baud model on your brand new Intel Pentium machine running Windows 95 was Rad and L33T.

For many of us, culture and music reached a pinnacle – MTV was still playing music videos.  You probably still listen to the music from that age - 2Pac and Biggie, WuTang and Big L – you remember Ja Rule and DMX, Brittany and No Doubt – Nirvana and Soundgarden and STP and when you hear Jock Jamz you're instantly transported back to a grade school or high school sports game – or maybe Mariah Carey's Hero” comes on the radio and you remember your first slow dances at the 8th grade mixer or maybe just remember watching Dennis Rodman and Michael Jordan go HAM on the court – or the bright neon scrunchies and Hot Topic studded belts or chain wallets on JNCO pants that sagged so low they defied the physics being taught in your high school classroom.

Sound familiar? You might just be a 90s kid – or maybe you wish you were. The 90s Ape Club was created as a place for 90s kids (both in age and spirit) to come together for the next big rise of the internet: into the Metaverse.

Their goal is to rekindle that nostalgia and control our own destiny in the Metaverse with multicultural collaboration, 90s themed parties around the globe, and building an impassioned vision of the future. They want to make sure that this important era is preserved on the blockchain forever – and you can be part of it.

The collection contains 5,555 apes generated by Artificial Intelligence. The first 1,000 were minted in the OG mint and boast special Genesis traits, making them extremely rare.

What was the mint price for Genesis Apes?
0.055 ETH 

What will be the mint price for presale and public sale?
Presale: 0.06 ETH Public sale: 0.08 ETH

Whitelisted members can mint up to 3 Apes per wallet during presale.

Any Apes that are not minted by whitelist members will be available in the public mint. During this mint, users will be able to purchase up to 10 Apes per wallet.

Utilities

Being a 90's Ape Club holder offers a number of impressive utilities as shown below:

Events

The team has proposed 2 NFT conferences and meetups in 2022 exclusively for holders. One of these meet-ups will be held in early August in Slovenia while the other will be held in North America with the exact location TBA. Holders will also attend special online NFT conferences for members that can't attend the IRL conferences. The goal is to share experiences and knowledge with the members as well as educate them about topics such as mental health and security in the NFT space, as well as the future of the metaverse.

Gaming

The team are currently developing their exclusive P2E game which is set in an alternative 1991 Hollywood called ‘Apewood'. You will assume the role of your NFT hero on a revenge rampage against the underworld. It will be inspired by some of GameBoys classics back in the 90's. Teasers of the game will be being released to the community in the near future. The game is set to be released in Q4. Alpha The team will also offer holders an alpha channel where they will have up-to-date information about existing and upcoming projects, exclusive whitelist opportunities, alpha alerts, special giveaways, and a host of other valuable information and benefits. 

Merch

In addition to the Alpha opportunities, members will have access to premium 90's Ape Club merchandise at exclusive prices. 20% of all Merchandise sales will be donated to a Monkey Sanctuary in New Zealand. Free t-shirts will also be provided for holders which we will distribute at one of the live conferences.

Metaverse

Sandbox and Decentraland integrations are coming in Q2 2022. 90s Ape Club holders will have access to private events in the Metaverse. More details about that will be announced soon.

The Public Mint date will be in April, the exact date is yet to be announced but you can keep up-to-date with all the latest 90's Ape Club news and information on the links provided below.

Social Media: 

Twitter: https://twitter.com/90sApeClub

Instagram: https://www.instagram.com/90sapeclub/

Opensea: https:// opensea.io/collection/90s-ape-club-v2

Discord: https://discord.gg/ hZfB3ngDTA

Media Details: 

Company Name: 90aspeclub 

Contact Name: Jaka

Email: 90sapeclub@gmail.com

Website: https://90sapeclub.io 


Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Recbio Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange

HONG KONG, Mar 21, 2022 - (ACN Newswire) - The China-based novel vaccines company - Jiangsu Recbio Technology Co., Ltd. ("Recbio" or the "Company", stock code: 2179.HK, today announced the proposed listing of its H Shares on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange").

Recbio plans to offer 30,854,500 H Shares (subject to the Over-allotment Option), of which 27,769,000 H Shares will be International Placing Shares (subject to reallocation and the Over-allotment Option), representing approximately 90% of the initial Offer Shares; the remaining 3,085,500 H Shares will be Hong Kong Offer Shares (subject to reallocation), representing approximately 10% of the initial Offer Shares. Recbio will open for Hong Kong Public Offering in Hong Kong at 9:00 a.m., 21 March 2022 (Monday), and close at 12:00 noon, 24 March 2022 (Thursday). Dealings in H Shares of Recbio on the Main Board of the Hong Kong Stock Exchange is expected to commence on 31 March 2022 (Thursday). The H Shares will be traded in board lot of 500 H Shares each. The Company's stock code is 2179.HK.

-- Morgan Stanley Asia Limited, CMB International Capital Limited and CLSA Capital Markets Limited are the Joint Sponsors; and Morgan Stanley Asia Limited, CMB International Capital Limited and CLSA Limited are the Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers.

-- China Industrial Securities International Capital Limited, Haitong International Securities Company Limited, GF Securities (Hong Kong) Brokerage Limited, Essence International Securities (Hong Kong) Limited and Valuable Capital Limited (in relation to the Hong Kong Public Offering only) are the Joint Bookrunners and Joint Lead Managers.

-- Livermore Holdings Limited is the Joint Lead Manager.

A Vaccine Pipeline Driven by Novel Adjuvant Technology
Recbio is the vaccine company with a high-value vaccine portfolio driven by in-house developed technologies. The Company is primarily focus on the R&D of HPV vaccine candidates. Its vaccine portfolio consists of 12 vaccines, including the Core Product, REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial, and the Company is one of the few domestic vaccine companies to have phase III stage HPV 9-valent vaccine candidate.

In recent years, vaccinology field has entered into a new era. Advanced technologies and breakthroughs in immunology have largely reshaped the vaccinology by creating opportunities for safer and more effective vaccine solutions. According to Frost & Sullivan, subunit vaccines accounted for approximately 55.4% of China's vaccine market in 2020, which is expected to further grow to 86.6% in 2030. Driven by the growing number of subunit vaccines and technology breakthroughs, China's vaccine market is expected to grow from RMB75.3 billion in terms of production value in 2020 to RMB333.3 billion in 2030 at a CAGR of 16.0%. With its strong R&D capabilities in developing subunit vaccines, the Company believe it is well-positioned to further benefit from the overall growth of China's vaccine market.

With years of dedication in developing vaccines and leveraging its in-house developed technology platforms, the Company has been built a comprehensive vaccine portfolio consisting of 12 candidates, covering a broad disease spectrum including cervical cancer, COVID-19, adult tuberculosis, shingles, HFMD and influenza. Its vaccine portfolio extends to five of the ten diseases with the greatest burden under the 2019 Global Burden of Diseases assessed by DALYs issued by the WHO and covers disease areas of the three of the top five globally bestselling vaccine products in 2020. The Core Product, REC603, is a recombinant HPV 9-valent vaccine candidate, which is currently under phase III clinical trial in China. The Company plan to submit the BLA application in 2025 for REC603 and commence commercialization once the BLA application is approved. In addition, its COVID-19 vaccine, ReCOV, has commenced a phase I clinical trial in New Zealand in June 2021 and obtained the initial partially unblinded data in October 2021. Based on the major safety and immunogenicity data and the partially unblinded efficacy data from the phase I trial, the Company subsequently obtained the clinical trial approval from the Philippines FDA to conduct the global phase II/III trial for ReCOV in January 2022. To date, the Company has initiated subject enrollment for the global phase II/III trial for ReCOV in the Philippines. In January 2022, the Company also obtained the unblinded clinical data for the remaining three cohorts and has been finalizing data analysis and clinical trial report. It plans to file the EUA/BLA application in 2022.

A Pipeline of Vaccine Candidates Covering Diseases With Significant Unmet Needs
The Company has adopted a vaccine development strategy aimed to firmly position itself at the vanguard of the vaccine industry. In light of overarching vaccine industry trends, it has strategically developed a pipeline that extends from preventative to post-exposure prophylaxis. In addition to HPV and COVID-19, its comprehensive pipeline also includes a recombinant shingles vaccine, two TB vaccines for adults, an influenza quadrivalent vaccine, and an HFMD quadrivalent vaccine.

HPV vaccines are one of the most commercially valuable vaccines in the world, with a global market size of US$4.2 billion in 2020, accounting for approximately 11.5% of the global vaccine market in terms of production volume. Therefore, the Company has strategically developed a comprehensive HPV pipeline to address the unmet urgent need for HPV vaccines. To date, the Company is advancing clinical trials of three key vaccine candidates namely a recombinant HPV 9-valent vaccine, REC603, and two recombinant bivalent vaccines, REC601 and REC602, targeting different countries and populations. At present, the Company is also developing REC604a and REC604b with a potentially fewer dose regimen, employing a self-developed novel adjuvant benchmarking AS04, and plans to submit INDs filing in 2022 and 2023, respectively.

What is noteworthy is that, its recombinant HPV 9-valent vaccine, REC603, is expected to be the one of the first of domestic vaccines of its kind to be approved and commercialized in China. The Company is currently conducting a phase III clinical trial and has completed 12,500 subjects enrollment for the potency tests in October 2021. The first subject was enrolled on June 26, 2021 and the Company is actively working with industry leading PIs and highly-qualified CROs to accelerate its trial progress. The Company expects to complete three-shot dosing by the first half of 2022 and plans to reach primary endpoints for its phase III clinical trial and submit BLA to the NMPA in 2025.

Self-Developed Advanced Technology Platforms that Support and Drive the Development of Next Generation Vaccine Candidates
Through years of dedication and focus on vaccinology field, the Company has developed a comprehensive vaccine innovation engine consisting of a novel adjuvant platform, protein engineering platform and immunological evaluation platform. The Company is the one of the few companies that are capable of developing novel adjuvants, benchmarking all of the FDA-approved novel adjuvants to date. The technology platforms form a solid trifecta, creating synergies among the design and optimization of antigens, the development and production of adjuvants and the identification of the optimal combinations of antigens and adjuvants. Supported by these platforms, the Company is constantly upgrading its technology to further enrich its R&D toolbox so that to drive its vaccine development going forward.

In addition to the technology platforms, its IPD System lays a solid foundation for the R&D activities. The IPD system governs the entire life cycle of vaccine candidates. Empowered by the IPD System, the Company is able to advance multiple vaccine development projects simultaneously.

Continuously Expand Production Capacity, Strengthen Competitive Advantage
The company has started to build up its manufacturing capabilities at an early stage to ensure the vaccine candidates can be smoothly transferred into successful commercial vaccine products. The manufacturing and quality control system is built in compliance with the industry leading GMP standard. It also has recruited many talents in charge of production and quality, who has gained abundant industry insights and profound understanding from their commercialization experience in vaccine companies.

Currently, the Company is constructing its HPV vaccine manufacturing facility in Taizhou, Jiangsu province, the first phase of which has a designed capacity of five million doses of HPV 9-valent vaccines or 30 million doses of HPV bivalent vaccines per year. The construction of the first phase of its HPV manufacturing facility is expected to be completed by the end of 2022. In addition, the Company has obtained a drug production license from ReCOV and completed the construction of the GMP-standard manufacturing facility for ReCOV in November 2021. The manufacturing facility, which can also be used for the manufacturing of recombinant shingles vaccines, has a total GFA of approximately 17,000 sq.m. and has the potential to support an annual manufacturing capacity of 300 million doses of ReCOV.

High Performance Management and Scientific R&D Team, Supported by Leading Investors in the Healthcare Industry
R&D is crucial to the continuous success. The vaccine industry has been rapidly evolving with various scientific advancement and innovative technologies to constantly reshape the vaccinology field. The Company is led by an experienced management and elite scientific team consisting of industry-leading scientists with extensive experiences in academic studies of immunology and development of vaccine products and industry-leading experts who are familiar with bringing vaccine candidates from concept to market.

The Company has also received strong support from its shareholders, including leading investors in healthcare industry as well as major institutional investor such as Lake Bleu Capital, Temasek, Legend Capital and Sequoia Capital, representing recognition from its shareholders on the market position and growth potential. The Company believe its diversified shareholder base will fuel the future growth with financial support and industry insights.

The Chairman of the Board, Executive Director and General Manager of Jiangsu Recbio Technology Co., Ltd., Dr. LIU Yong said, "As the vaccinology field enters a new era driven by novel vaccine technologies and significant expansion in disease and population coverage, we expect that China's vaccine market will grow significantly. With our strong R&D capabilities, we expect to further benefit from the overall growth in China's vaccine market. Looking ahead, we plan to continuously accelerate R&D, clinical trial and commercialization of our vaccine candidates, including rapidly advancing the development of our HPV vaccines, COVID-19 vaccines as well as the development and commercialization of our other vaccine candidates. We also intend to boost our market penetration and profitability by encouraging continuous innovation, streamlining our organization structure, company culture, and talent recruiting system, commercializing our technologies and products in the global market, and expanding vaccine candidates and technologies internationally through collaboration. At the same time, we will continue to explore opportunities to acquire advanced technologies and recruit international talent to supplement our in-house R&D capabilities. We are also evaluating establishing an overseas R&D center to closely collaborate with academic institutes and scientists abroad and to advance our R&D activities. Finally, driven by our strong R&D capabilities, we are focusing on complete value chain innovation from R&D to commercialization in the vaccine industry, to maximize value for our shareholders and investors."

Use of Proceeds:

The Company estimates that it will receive net proceeds of approximately HK$672.4 million from the Global Offering, after deducting the underwriting commissions and other estimated offering expenses payable by the Company, assuming the Over-allotment Option is not exercised and assuming the Offer Price is fixed at HK$24.80 per H Share. The Company intends to use the net proceeds for the following purposes:

-- Approximately 47.3%, or HK$317.9 million, will be allocated to continue to optimize, develop and commercialize HPV vaccine pipeline, including the Core Product, the recombinant HPV 9-valent vaccine REC603

-- Approximately 17.7%, or HK$119.3 million, will be used for the preclinical and clinical studies, registration of the COVID-19 vaccine, namely ReCOV

-- Approximately 21.1%, or HK$142.0 million, will be used for the preclinical and clinical studies, registration of other vaccine candidates, including recombinant shingles vaccine, REC610; TB vaccines, REC606; and REC607, recombinant quadrivalent influenza vaccine, REC617; and recombinant HFMD quadrivalent vaccine, REC605

-- Approximately 6.7%, or HK$44.7 million, will be used to further enhance the R&D capabilities and enhance its operating efficiencies

-- Approximately 7.2%, or HK$48.5 million, will be used for working capital and general corporate purposes


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comThe China-based novel vaccines company - Jiangsu Recbio Technology Co., Ltd. ("Recbio" or the "Company", stock code: 2179.HK, today announced the proposed listing of its H Shares on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange").

Week Ahead – Accelerated tightening

Central banks playing catch-up The global economy is facing an incredible amount of uncertainty at the moment which is continuing to drive the volatility we’re seeing in financial markets. Whether it’s uncertainty around inflation, interest rates, commodity prices, Covid or Ukraine, the growth outlook has become extremely unclear and is constantly subject to significant revisions. […]

Week Ahead – Central banks

Rate hikes expected as inflation keeps rising It’s been another volatile week in financial markets with events in and around Ukraine continuing to dominate. Sentiment is still very headline-driven and an enormous amount of uncertainty remains around the outcome of talks between Ukraine and Russia and the sanctions being imposed on the latter by the […]

NZ dollar dips despite strong mfg. data

The New Zealand dollar’s mini-rally has come to a halt, as NZD/USD has posted slight losses. In the North American session, NZD/USD is trading at 0.6845, down 0.21% on the day. NZ Manufacturing PMI expands New Zealand’s manufacturing sector posted strong numbers this week. Earlier today, Manufacturing PMI accelerated to 53.6 in February, up from […]

Bank Freedom Finance Kazakhstan JSC Launches a Digital Mortgage

Almaty, The Republic of Kazakhstan, Mar 10, 2022 - (ACN Newswire) - Bank Freedom Finance Kazakhstan JSC announces they have digitized mortgage loan by 90%. At the same time in leading countries such as Finland, South Korea, Sweden, USA the level of digitalization of mortgage products reaches just over 30%. In the UK, it is 55%.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

The UN's 2020 study examined 193 countries in terms of their level of e-government development (E-Government Development Index). This index consists of the arithmetic mean of three indicators: the breadth and quality of online services, the level of development of telecommunications infrastructure and the amount of human capital.

Denmark, South Korea, Estonia, Finland, Australia, Sweden, Great Britain, New Zealand, the United States and the Netherlands are at the top of the list of most digitized countries. Kazakhstan was ranked 29th, with first place among the CIS countries.

To understand the level of digitalization of the mortgage loan process, the top banks in the above countries were studied in terms of digitalization. The following mortgage origination steps were considered and tested: application - pre-approval – real estate valuing - decision - deal execution - signing of documents - registration of a pledge - disbursement in the moment - post-service. The analysis showed that the international examples used a hybrid scheme - where online processes are combined with offline ones.

In Kazakhstan's digital mortgage, all stages are digitized except for the last one, when a meeting with a notary is required to sign the Purchase and Sale Agreement. This cannot be done remotely under the Law of the Republic of Kazakhstan. But even with the last step, mortgage processing takes a day. No paper documents are required - the system itself collects them from state databases, the real estate valuing is done online, the pledge is registered remotely, and an electronic digital signature can be issued in the process.

Media Contact
Brand: Bank Freedom Finance Kazakhstan JSC
Contact: Rakhilya Mirzalimova, Head of PR department
E-Mail: rm@bankffin.kz
Telephone: +77017680566
Website: https://bankffin.kz/

SOURCE: Bank Freedom Finance Kazakhstan JSC



Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com

ClearSoftware teams with Zellim in launch of DAO productivity & communications platform

Zellim, an integrated software solutions company, today announced a partnership with ClearSoftware, a build of decentralized systems, to launch a new decentralized autonomous organization (DAO) platform. The joint efforts will result in decentralized integration of Zellim’s all-in-one productivity platform. Many of Clear’s companies and organizations operate as decentralized autonomous organizations (DAOs) with offices all over […]

The post ClearSoftware teams with Zellim in launch of DAO productivity & communications platform appeared first on CryptoNinjas.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Recent articles

spot_img